In the study using transgenic mice that express a constitutively active FXR in the intestine, the selective activation of FXR in the intestine protected the liver from cholestasis by increasing the FGF15 expression and decreasing the hepatic BA pool [112]. The gene discussed is NR1H4; the disease is cholestasis.